TY - JOUR
T1 - Non-Sugar-Sweetened Beverages and Risk of Chronic Diseases
T2 - An Umbrella Review of Meta-analyses of Prospective Cohort Studies
AU - Beigrezaei, Sara
AU - Raeisi-Dehkordi, Hamidreza
AU - Hernández Vargas, Juliana Alexandra
AU - Amiri, Mojgan
AU - Artola Arita, Vicente
AU - van der Schouw, Yvonne T
AU - Salehi-Abargouei, Amin
AU - Muka, Taulant
AU - Chatelan, Angeline
AU - Franco, Oscar H
N1 - Publisher Copyright:
© The Author(s) 2024. Published by Oxford University Press on behalf of the International Life Sciences Institute.
PY - 2025/4/1
Y1 - 2025/4/1
N2 - Context: Several effects of non–sugar-sweetened beverage (NSSBs) intake on health outcomes have been reported; however, the evidence on the association between NSSBs intake and chronic diseases and mortality risk is still inconclusive. Objective: This umbrella review aimed to summarize the evidence on the association between NSSBs intake and the risk of chronic diseases and mortality. Data Sources: Embase, ISI Web of Science, Cochrane Central, and PubMed were searched up to September 2023 for relevant meta-analyses of observational prospective cohort studies. Data Extraction: Two groups of researchers independently extracted study data and assessed the risk of bias for meta-analyses and primary studies. Data Analysis: Six meta-analyses, reporting 74 summary hazard ratios (HRs) for different outcomes obtained from 50 primary studies, were included. The summary HRs, 95% CIs, and certainty of evidence on the association of NSSBs intake with risk of chronic diseases and mortality were as follows: all-cause mortality (per 355 mL/d: 1.06 [1.01 to 1.10]; moderate certainty); stroke (per 250 mL/d: 1.09 [1.04 to 1.13]; high certainty); coronary heart disease (CHD) (per 250 mL/d: 1.06 [1.02 to 1.11]; high certainty); hypertension (HTN) (high vs low intake: 1.14 [1.09 to 1.18]; moderate certainty); type 2 diabetes (T2D) (high vs low intake: 1.16 [1.08 to 1.26]; low certainty); metabolic syndrome (MetS) (high vs low intake: 1.32 [1.22 to 1.43]; low certainty); colorectal cancer (high vs low intake: 0.78 [0.62 to 0.99]; moderate certainty); and leukemia (high vs low intake: 1.35 [1.03 to 1.77]; moderate certainty). For other outcomes, including the risk of cardiovascular and cancer mortality, chronic kidney diseases, breast cancer, prostate cancer, endometrial cancer, pancreatic cancer, multiple myeloma, and non-Hodgkin lymphoma, no association was found. Conclusion: This study provides further evidence that NSSBs are associated with increased risk of all-cause mortality, stroke, CHD, HTN, T2D, MetS, and leukemia. Moreover, a higher intake of NSSBs was associated with a lower risk of colorectal cancer. However, it should be noted that the magnitudes of the associations are not large. Further studies are needed to clarify the long-term effects of different NSSBs intakes on health.
AB - Context: Several effects of non–sugar-sweetened beverage (NSSBs) intake on health outcomes have been reported; however, the evidence on the association between NSSBs intake and chronic diseases and mortality risk is still inconclusive. Objective: This umbrella review aimed to summarize the evidence on the association between NSSBs intake and the risk of chronic diseases and mortality. Data Sources: Embase, ISI Web of Science, Cochrane Central, and PubMed were searched up to September 2023 for relevant meta-analyses of observational prospective cohort studies. Data Extraction: Two groups of researchers independently extracted study data and assessed the risk of bias for meta-analyses and primary studies. Data Analysis: Six meta-analyses, reporting 74 summary hazard ratios (HRs) for different outcomes obtained from 50 primary studies, were included. The summary HRs, 95% CIs, and certainty of evidence on the association of NSSBs intake with risk of chronic diseases and mortality were as follows: all-cause mortality (per 355 mL/d: 1.06 [1.01 to 1.10]; moderate certainty); stroke (per 250 mL/d: 1.09 [1.04 to 1.13]; high certainty); coronary heart disease (CHD) (per 250 mL/d: 1.06 [1.02 to 1.11]; high certainty); hypertension (HTN) (high vs low intake: 1.14 [1.09 to 1.18]; moderate certainty); type 2 diabetes (T2D) (high vs low intake: 1.16 [1.08 to 1.26]; low certainty); metabolic syndrome (MetS) (high vs low intake: 1.32 [1.22 to 1.43]; low certainty); colorectal cancer (high vs low intake: 0.78 [0.62 to 0.99]; moderate certainty); and leukemia (high vs low intake: 1.35 [1.03 to 1.77]; moderate certainty). For other outcomes, including the risk of cardiovascular and cancer mortality, chronic kidney diseases, breast cancer, prostate cancer, endometrial cancer, pancreatic cancer, multiple myeloma, and non-Hodgkin lymphoma, no association was found. Conclusion: This study provides further evidence that NSSBs are associated with increased risk of all-cause mortality, stroke, CHD, HTN, T2D, MetS, and leukemia. Moreover, a higher intake of NSSBs was associated with a lower risk of colorectal cancer. However, it should be noted that the magnitudes of the associations are not large. Further studies are needed to clarify the long-term effects of different NSSBs intakes on health.
KW - artificially sweetened beverages
KW - cancer
KW - cardiovascular disease
KW - chronic disease
KW - low-calorie sweeteners
KW - mortality
KW - no-calorie sweeteners
KW - type 2 diabetes
KW - umbrella review
UR - http://www.scopus.com/inward/record.url?scp=105000083285&partnerID=8YFLogxK
U2 - 10.1093/nutrit/nuae135
DO - 10.1093/nutrit/nuae135
M3 - Article
C2 - 39325512
SN - 0029-6643
VL - 83
SP - 663
EP - 674
JO - Nutrition Reviews
JF - Nutrition Reviews
IS - 4
M1 - doi.org/10.1093/nutrit/nuae135
ER -